QantX
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Revolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins
Revolver Therapeutics develops peptide-based therapeutics designed to inhibit transcription factors, proteins inside cancer cells that drive tumour growth, survival and treatment resistance. Its Transcription Block Survival platform identifies cell-penetrating peptides that can switch off these targets, which have traditionally been considered too difficult to reach with conventional drugs.
Neuronostics raises £3m in funding led by Empirical Ventures and The FSE Group for platform that diagnoses epilepsy from brain activity recordings
Neuronostics develops BioEP, a digital biomarker platform that analyses EEG recordings to support the diagnosis and prognosis of epilepsy. The platform is designed for clinicians who need objective decision support when routine EEG results are inconclusive.
EnsiliTech raises £4.5m seed round led by Eos Advisory to transform global medicine storage and transport
EnsiliTech develops technology that stabilises vaccines and biologics at high temperatures, removing the need for cold-chain storage and improving global access to medicines.
- 3(12 months)
- qantx.co.uk
- Update Information
More venture news
- 29 Jul 2026
LevelTechLevels Technologies secures £500k in funding led by The FSE Group for its player rating and rankings platform for racket sports
EquityConsumer - 29 Jul 2026
MASAJMASAJ raises £1.5m in funding led by FIGR Ventures and Sorven Capital to roll out massage studio chain across London
EquityConsumer - 28 Jul 2026
Perceptual RoboticsPerceptual Robotics lands £4m led by Investing for Purpose for autonomous drone inspection of wind turbine blades
EquityEnergy
